Topic

Pennsylvania

A collection of 524 issues

How to Get Pyrukynd (Mitapivat) Covered by Cigna in Pennsylvania: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Pyrukynd Covered by Cigna in Pennsylvania Cigna requires prior authorization for Pyrukynd (mitapivat) in Pennsylvania for adults with pyruvate kinase deficiency, confirmed by genetic testing (≥2 PKLR gene variants with ≥1 missense variant) and prescribed by a hematologist. You'll need hemoglobin ≤10 g/dL or

Getting Kymriah Approved by UnitedHealthcare in Pennsylvania: Complete Coverage Guide with Appeals Process

Answer Box: Fast Track to Kymriah Coverage UnitedHealthcare covers Kymriah (tisagenlecleucel) as a medical benefit requiring prior authorization through OptumHealth Transplant Solutions. Key requirements: CD19+ confirmed disease, ≥2 prior therapy failures, treatment at FACT-accredited center. First step today: Verify your plan includes transplant benefits and confirm your treatment center is

UnitedHealthcare's Coverage Criteria for Tecentriq (atezolizumab) in Pennsylvania: What Counts as "Medically Necessary"?

Answer Box: Getting Tecentriq Covered by UnitedHealthcare in Pennsylvania UnitedHealthcare requires prior authorization for Tecentriq (atezolizumab) with specific medical necessity criteria including FDA-approved indication, PD-L1 testing (when required), and oncologist prescribing. If denied, Pennsylvania's Independent External Review Program has overturned 53% of denials. Start today: Gather your pathology

Work With Your Doctor to Get Vimizim (Elosulfase Alfa) Approved by UnitedHealthcare in Pennsylvania: Medical Necessity Letters, Appeals, and Provider Collaboration

Answer Box: Getting Vimizim Approved in Pennsylvania UnitedHealthcare requires prior authorization for Vimizim (elosulfase alfa) through OptumRx, with strict diagnostic and functional requirements for MPS IVA patients. Your fastest path: (1) Schedule with a pediatric geneticist or metabolic specialist at Children's Hospital of Philadelphia or Nemours, (2) Gather

How to Get Tagrisso (Osimertinib) Covered by Cigna in Pennsylvania: Complete Guide to Prior Authorization and Appeals

Answer Box: Getting Tagrisso Covered by Cigna in Pennsylvania Cigna covers Tagrisso (osimertinib) with prior authorization for EGFR mutation-positive NSCLC. Your fastest path to approval: 1. Confirm EGFR mutation status via FDA-approved testing (exon 19 deletion, L858R, or T790M) 2. Submit PA through Cigna provider portal using form CNF-550 with

How to Get Xenpozyme (olipudase alfa-rpcp) Covered by Blue Cross Blue Shield in Pennsylvania: Complete Coding, Appeals, and Authorization Guide

Answer Box: Getting Xenpozyme Covered in Pennsylvania Xenpozyme (olipudase alfa-rpcp) requires prior authorization from Blue Cross Blue Shield plans in Pennsylvania. Use ICD-10 codes E75.240 (type A), E75.241 (type B), or E75.244 (type A/B) for ASMD diagnosis. Submit PA with genetic confirmation, baseline organ assessments, and

How to Get Tracleer (bosentan) Covered by Blue Cross Blue Shield in Pennsylvania: Complete Prior Authorization Guide

Answer Box: Getting Tracleer (bosentan) Covered in Pennsylvania Blue Cross Blue Shield plans in Pennsylvania require prior authorization for Tracleer (bosentan) with specific REMS program enrollment. The fastest path to approval: 1) Enroll prescriber and patient in the Bosentan REMS Program, 2) Submit PA request with PAH diagnosis confirmation and

How to Get Ocrevus (Ocrelizumab) Covered by Blue Cross Blue Shield in Pennsylvania: Complete Timeline and Appeals Guide

Answer Box: Getting Ocrevus Covered by Blue Cross Blue Shield in Pennsylvania Blue Cross Blue Shield Pennsylvania requires prior authorization for Ocrevus (ocrelizumab) with specific clinical criteria: confirmed MS diagnosis, age 18+, negative hepatitis B screening, and documentation of prior DMT trials or contraindications. Submit PA requests through your plan&

Getting Zanzalintinib (XL092) Covered by UnitedHealthcare in Pennsylvania: Clinical Trial Access and Compassionate Use Appeals Guide

Answer Box: Your Fastest Path to Zanzalintinib Coverage Getting Zanzalintinib (XL092) covered by UnitedHealthcare in Pennsylvania requires clinical trial enrollment or compassionate use approval, since this investigational TKI has no FDA approval. Your three options: (1) Enroll in an active STELLAR program trial where UnitedHealthcare covers routine monitoring costs, (2)

How to Get Gamifant (Emapalumab-lzsg) Covered by Blue Cross Blue Shield in Pennsylvania: Complete Timeline and Appeal Guide

Answer Box: Getting Gamifant Covered by Blue Cross Blue Shield in Pennsylvania Blue Cross Blue Shield requires prior authorization for Gamifant (emapalumab-lzsg) with documented HLH diagnosis using 5 of 8 HLH-2004 criteria OR genetic confirmation, plus failure/intolerance to conventional therapy (etoposide, dexamethasone, cyclosporine). Standard PA decisions take 14-30 days;